A reference work, not a recommendation to use: this profile describes mechanism and evidence and does not replace medical advice. The claims come from marketing and forums and are tested here, not endorsed.

Mechanism of action

Evidence map: Alpha-GPC

Each line stands for a published finding; line style and color show where it comes from. The filter hides weaker evidence levels. Sources: see references.

After oral intake, alpha-GPC is cleaved in the intestinal mucosa to glycerophosphate and free choline and is thereby supposed to enlarge the supply of choline for acetylcholine synthesis [1]. In rats, it abolished the memory impairment induced by scopolamine and attenuated the drop in acetylcholine in the hippocampus and cerebral cortex, but not in the striatum [1]. Microdialysis measurements showed a dose-dependent increase in acetylcholine release in the hippocampus; radiolabeled alpha-GPC was converted to acetylcholine [2].

In humans, in a small randomized crossover study in six healthy men, choline and betaine in the blood rose after alpha-GPC to a similar extent as after other choline supplements; all water-soluble supplements at the same time rapidly raised trimethylamine N-oxide (TMAO), which gut bacteria form from choline [3]. In young and older volunteers, alpha-GPC enhanced the release of growth hormone after stimulation with GHRH, which fits an increased cholinergic tone [4]. It did not change inflammatory markers in the rat brain [5].

Clinically, alpha-GPC has been studied mainly in dementia. In a multicenter RCT of 261 people with mild to moderate Alzheimer's dementia, it improved ADAS-Cog, MMSE, and further scales over 180 days compared with placebo [6]. A meta-analysis found advantages mainly in combination with donepezil [7]; its last author has himself published studies on this combination (ASCOMALVA) [8]. Older reviews rely in part on uncontrolled studies [9].

Targets

TargetTypeActionKey dataEvidence
Choline supply for acetylcholine synthesisOtherRelease Animal study[1][2]

Effect profile

Which signaling systems the compound affects according to current data. ↑ enhanced, ↓ dampened, ≈ modulated, ○ no effect; dots = evidence level.

  • Dopamineno data
  • Noradrenalineno data
  • Serotoninno data
  • Acetylcholine↑ · more acetylcholine release in the hippocampus (rat); not measured directly in humans[1][2]
  • Glutamate · AMPAno data
  • Glutamate · NMDAno data
  • GABAno data
  • Histamineno data
  • Orexinno data
  • Adenosineno data
  • Opioidsno data
  • Melatoninno data
  • Neurotrophinsno data
  • Blood flowno data
  • Nitric oxideno data
  • Energy metabolismno data
  • Insulin · glucoseno data
  • Inflammation · oxidativeno effect · no change in inflammatory markers in the rat brain[5]
  • Stress axisno data
  • Testosterone axisno data
  • Endocannabinoidsno data
  • Autophagy · senescenceno data
  • Immune systemno data
  • Lipid metabolismno data
  • Coagulation · fibrinolysisno data
  • Methylationno data

Human studies

  • Alzheimer's dementia, 180 days

    RCT, double-blind, placebo-controlled, multicenter · Patients: mild to moderate Alzheimer's dementia · n = 261 · 180 days

    Measured: ADAS-Cog, MMSE, GDS, CGI

    Result: ADAS-Cog −3.20 points with alpha-GPC vs. +2.90 with placebo after 180 days; significant differences on several scales.[6]

    Human, randomised

  • Meta-analysis of cognitive disorders

    systematic review and meta-analysis (7 RCTs, 1 cohort) · Patients: cognitive disorders with onset in adulthood · varying

    Measured: Cognition, function, behavior

    Result: With donepezil, cognition better (MD 1.72; 95% CI 0.20–3.25); alpha-GPC versus placebo or other agents MD 3.50 (0.36–6.63).[7]

    Human, randomised

  • Cognition after a single dose in healthy men

    RCT, double-blind, placebo-controlled, crossover · healthy (resistance-trained men) · n = 20 · Single dose

    Measured: Stroop, N-back, flanker

    Result: Stroop total score better (d = 0.48–0.61); N-back and flanker without a difference. The author advises the sponsor.[11]

    Human, randomised

  • Strength and vigilance after seven days

    RCT, placebo-controlled · healthy (students) · n = 48 · 7 days

    Measured: Jump power, isometric strength, psychomotor vigilance (PVT)

    Result: No difference in vigilance and isometric strength; jump values better only at the lower strength.[12]

    Human, randomised

  • Motivation in everyday life

    RCT, single-blind, placebo-controlled · healthy · n = 39 · 2 weeks

    Measured: self-reported emotional state (KOKORO scale)

    Result: Trend toward more motivation, significant in the evening; no effect on anxiety.[13]

    Human, randomised

  • Stroke risk in users

    retrospective cohort (insurance data) · Adults aged 50 and older without stroke or Alzheimer's disease · n = 12008977 · Follow-up 2009–2018

    Measured: Stroke overall, ischemic, hemorrhagic

    Result: After matching, higher stroke risk in users (aHR 1.43; 95% CI 1.41–1.46), dose-dependent; observational data, no causality.[10]

    Human, non-randomised

Risks and warnings

  • Higher stroke risk (observational data)

    In a cohort of 12 million people aged 50 and older, users had a stroke risk about 40% higher after adjustment for many risk factors, with a dose-response relationship. As an observational study, it does not prove a cause; reasons for prescription could play a role [10].

    Human, non-randomised

  • Rise in TMAO

    Alpha-GPC rapidly raised TMAO in the blood, as did other water-soluble choline supplements [3]. Whether this is clinically harmful is unresolved; the cohort study names TMAO as a possible mechanism [10].

    Human, randomised

  • Lowering of TSH

    At the higher of two strengths, thyroid-stimulating hormone (TSH) was significantly lower after seven days [12]. Significance unclear.

    Human, randomised

Interactions

  • Donepezil: Given as a combination in studies; the meta-analysis found better values with the combination than with donepezil alone [7].

Fact check: common claims

  • partly supported

    “Alpha-GPC increases acetylcholine in the brain”

    In rats, more acetylcholine release in the hippocampus [1][2]; not measured directly in humans, only indirectly via choline in the blood [3] and growth hormone [4].

  • partly supported

    “Alpha-GPC improves focus and memory in healthy people”

    A small, sponsor-related RCT found a better Stroop test but no effect in two further tests [11]; another RCT found no effect on vigilance [12].

  • not supported

    “Alpha-GPC increases strength and growth hormone”

    More growth hormone only after additional GHRH stimulation [4]; in RCTs, no difference in growth hormone and strength after training [11] and in isometric strength [12].

  • partly supported

    “Alpha-GPC helps in Alzheimer's dementia”

    One positive RCT over 180 days [6] and a meta-analysis with advantages mainly together with donepezil [7]; independent confirmations in large studies are lacking.

  • not supported

    “Alpha-GPC is harmless as a food ingredient”

    A large observational study shows a higher stroke risk in users [10]; a cause has not been proven, but has not been ruled out either.

Pharmacokinetics

Absorption
Oral; cleavage in the intestinal mucosa to glycerophosphate and choline [1]. Plasma choline rose similarly to after other choline supplements [3].
Half-life
Not verified.
Metabolism
Choline is converted in part to betaine, in part to TMAO by gut bacteria [3].
Entry into the brain
Radiolabeled alpha-GPC was converted to acetylcholine in the rat brain [2].

Legal status

Germany
Not verified.
EU
Authorized as a medicinal product in individual countries since 1985; classification as a prescription-only medicinal product differs from country to country [7].
USA
Not verified.
Other countries
South Korea: prescribed by physicians, recorded in a nationwide insurance database [10].

Related compounds

Citicolinesame classCentrophenoxinsame class (German only)

Open questions

  • Is the higher stroke risk in the Korean cohort causal or due to the reasons for prescription?
  • Does alpha-GPC achieve a measurably higher acetylcholine release in the brain in humans?
  • Can the positive Alzheimer's findings be replicated in independent, large RCTs?

References

  1. Lopez CM, Govoni S, Battaini F, Bergamaschi S, Longoni A, Giaroni C, et al. Effect of a new cognition enhancer, alpha-glycerylphosphorylcholine, on scopolamine-induced amnesia and brain acetylcholine. Pharmacol Biochem Behav. 1991;39(4):835–40. doi:10.1016/0091-3057(91)90040-9 · PubMed
  2. Sigala S, Imperato A, Rizzonelli P, Casolini P, Missale C, Spano P. L-alpha-glycerylphosphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat. Eur J Pharmacol. 1992;211(3):351–8. doi:10.1016/0014-2999(92)90392-h · PubMed
  3. Böckmann KA, Franz AR, Minarski M, Shunova A, Maiwald CA, Schwarz J, et al. Differential metabolism of choline supplements in adult volunteers. Eur J Nutr. 2022;61(1):219–30. doi:10.1007/s00394-021-02637-6 · PubMed
  4. Ceda GP, Ceresini G, Denti L, Marzani G, Piovani E, Banchini A, et al. alpha-Glycerylphosphorylcholine administration increases the GH responses to GHRH of young and elderly subjects. Horm Metab Res. 1992;24(3):119–21. doi:10.1055/s-2007-1003272 · PubMed
  5. Tayebati SK, Martinelli I, Moruzzi M, Amenta F, Tomassoni D. Choline and choline alphoscerate do not modulate inflammatory processes in the rat brain. Nutrients. 2017;9(10):1084. doi:10.3390/nu9101084 · PubMed
  6. De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer’s dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther. 2003;25(1):178–93. doi:10.1016/s0149-2918(03)90023-3 · PubMed
  7. Sagaro GG, Traini E, Amenta F. Activity of choline alphoscerate on adult-onset cognitive dysfunctions: a systematic review and meta-analysis. J Alzheimers Dis. 2023;92(1):59–70. doi:10.3233/JAD-221189 · PubMed
  8. Rea R, Carotenuto A, Traini E, Fasanaro AM, Manzo V, Amenta F. Apathy treatment in Alzheimer’s disease: interim results of the ASCOMALVA trial. J Alzheimers Dis. 2015;48(2):377–83. doi:10.3233/JAD-141983 · PubMed
  9. Parnetti L, Amenta F, Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mech Ageing Dev. 2001;122(16):2041–55. doi:10.1016/s0047-6374(01)00312-8 · PubMed
  10. Lee G, Choi S, Chang J, Choi D, Son JS, Kim K, et al. Association of L-α glycerylphosphorylcholine with subsequent stroke risk after 10 years. JAMA Netw Open. 2021;4(11):e2136008. doi:10.1001/jamanetworkopen.2021.36008 · PubMed
  11. Kerksick CM. Acute alpha-glycerylphosphorylcholine supplementation enhances cognitive performance in healthy men. Nutrients. 2024;16(23):4240. doi:10.3390/nu16234240 · PubMed
  12. Marcus L, Soileau J, Judge LW, Bellar D. Evaluation of the effects of two doses of alpha glycerylphosphorylcholine on physical and psychomotor performance. J Int Soc Sports Nutr. 2017;14:39. doi:10.1186/s12970-017-0196-5 · PubMed
  13. Tamura Y, Takata K, Matsubara K, Kataoka Y. Alpha-glycerylphosphorylcholine increases motivation in healthy volunteers: a single-blind, randomized, placebo-controlled human study. Nutrients. 2021;13(6):2091. doi:10.3390/nu13062091 · PubMed
How this profile was checked

Last reviewed: 2026-10-23. All sources with a DOI or PMID were resolved automatically via Crossref or doi.org and PubMed.

Translated from the German profile (version of 2026-10-23); translation checked on 2026-10-26.

Checked

  • All DOIs resolved via Crossref, PMIDs match the DOIs.
  • Checked against the abstract: cleavage in the gut, hippocampus/cortex, not striatum [1]; microdialysis, [14C]acetylcholine [2]; n = 6, same choline AUC, TMAO rise [3]; GH after GHRH [4]; no inflammatory markers [5]; n = 261, ADAS-Cog −3.20 vs. +2.90 [6]; 7 RCTs + 1 cohort, MD 1.72 and 3.50, authorization 1985 and differences between countries [7]; 13 studies, uncontrolled stroke studies [9]; n = 20, Stroop d = 0.48/0.61, N-back/flanker without effect, consulting for the sponsor [11]; n = 48, PVT without effect, TSH lowered [12]; n = 39, single-blind [13]; 12,008,977 people, aHR 1.43 [10]. Author list of [8] (Amenta F as last author).
  • ClinicalTrials.gov: 38 entries for “choline alfoscerate”, 12 for “alpha-GPC” (overlap not checked; October 23, 2026).
  • Precision flags (m004; rules of the guideline of October 26, 2026; participant numbers, direction, and funding checked on October 26, 2026 via PubMed efetch against the abstract, conflict-of-interest statement, and affiliations): “Better mental performance in healthy people”: “kleine_studien” – [11] 20, [12] 48, [13] 39.
  • October 26, 2026, cross-check of the precision flags (m004): evidence for the flags set also added to the begruendung (“Evidence for …”, guideline “Präzisions-Flags”); figures and statements checked again via PubMed efetch (abstract, conflict-of-interest and funding statements, affiliations): “Better mental performance in healthy people”: [11] 20, [12] “Forty-eight”, [13] “Thirty-nine”.

Not verified

  • An erratum was published for [10] in 2026 (JAMA Netw Open 2026;9(9):e2639482); content not checked.
  • Legal status in Germany and the US (medicinal product or dietary supplement) not checked in registers.
  • Study design of [4] (randomization, sample size) not described in the abstract.
  • Number of participants in the meta-analysis [7] not given in the abstract.

No dosages, no sources of supply. This information does not replace medical advice.

Spotted an error or missing something?

Request a compound, suggest an improvement or report an error. Every message is read.

Type of message

The website stores nothing. The button opens your email app with a pre-filled message.